Clinical trials: Disease Exacerbation
Asthma
Asthma Exacerbation Study
This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
- Trial name
- NCT01086384
- Testing
- Fluticasone Furoate/GW642444, Fluticasone furoate
- Where
- 183 sites in United States, Argentina and 9 more
- Volunteers
- 2,020 people
- Sponsor
- GlaxoSmithKline
Bronchiectasis, Acute Exacerbation of Bronchiectasis
Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis: A Randomized, Multi-center, Double-blind Study
This is a multi-center, randomized, double-blind, parallel-group trial. After a 2-week run-in period, eligible patients will be, based on the randomization codes kept in sealed envelopes, randomly assigned to receive usual care…
- Conditions
- Bronchiectasis, Acute Exacerbation of Bronchiectasis, Oxidative Stress
- Trial name
- HYBRID (NCT02765295)
- Testing
- medical ultrasonic hydrogen/oxygen nebulizer (MUNHO), Medical molecular mesh oxygen generator
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Cystic Fibrosis
Mucin in Sputum of CF During Pulmonary Exacerbation
The purpose of this study is to determine whether mucin is increased during pulmonay exacerbations in adult patients with cystic fibrosis (CF).
- Trial name
- NCT00202072
- Where
- 2 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Philipps University Marburg
Asthma
Exacerbation Risk in Asthma
The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
- Trial name
- NCT05501639
- Testing
- tiotropium, long-acting β2-agonists (LABA), inhaled corticosteroids (ICS)
- Where
- United States
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia.
- Trial name
- NCT00768612
- Testing
- SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Joint Pain, Knee Osteoarthritis
Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation
This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial designed to evaluate the efficacy and safety of a fixed-dose combination of celecoxib and acetaminophen compared to celecoxib monotherapy for…
- Conditions
- Joint Pain, Knee Osteoarthritis, Hip Osteoarthritis
- Trial name
- PRECEDENT (NCT06863636)
- Testing
- Celecoxib + Acetaminophen, Celecoxib
- Where
- Mexico
- Volunteers
- 231 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
COPD, Muscle Weakness
Feasibility of Strength Training in Patients Hospitalized Due to COPD
To examine the feasibility of progressive unilateral knee-extension strength training using ankle weight cuffs in patients hospitalized due to acute exacerbation in COPD
- Trial name
- NCT01981200
- Testing
- Resistance training in AECOPD
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Frederikssunds Hospital, Denmark
Chronic Respiratory Conditions, COPD
The AcCREDiT 2 Study
The ACCREDIT study - Acute respiratory infections and chronic respiratory disease exacerbations characterisation and personalised treatment platform study 2 (AcCREDiT 2).
- Conditions
- Chronic Respiratory Conditions, COPD, Pneumonia, Bacterial Infections
- Trial name
- ACCREDIT2 (NCT07029672)
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Manchester University NHS Foundation Trust
Pulmonary Disease, Chronic Obstructive
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD.
- Trial name
- NCT00563381
- Testing
- Tiotropium bromide, Salmeterol
- Where
- 752 sites in Austria, Belgium and 23 more
- Volunteers
- 7,376 people
- Sponsor
- Boehringer Ingelheim
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Effect of Compound Sodium Chlorate and Aminophylline Tablets on Chronic Obstructive Pulmonary Disease(COPD).
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an important event in the management of chronic obstructive pulmonary disease.
- Trial name
- NCT04101500
- Testing
- Compound Ipratropium Bromide Solution(C1) for Inhalation, Compound Sodium Chlolate and Aminophylline Tablets(C2)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
SARS-CoV-2 Infection
Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19
Primary: The primary objective of this study is to evaluate the efficacy of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not…
- Trial name
- NCT05599919
- Testing
- Nitric Oxide
- Where
- 21 sites in India
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Sanotize Research and Development corp.
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline
Long COVID
Feasibility of an Augmented Two-Day Step Test and Causal Modeling for Post-Exertional Symptom Exacerbation in Post Covid-19 Syndrome
This study aims to evaluate exercise capacity and identify causes of Post-Exertional Symptom Exacerbation (PESE) in individuals with Long COVID.
- Trial name
- REVEAL (NCT06933017)
- Testing
- Portable mask for respiratory gas analysis, Cardio-pulmonary exercise test
- Where
- 2 sites in Belgium
- Volunteers
- 25 people
- Sponsor
- Universitair Ziekenhuis Brussel
Ulcerative Colitis, Ulcerative Colitis Exacerbation
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract of unknown etiology. UC is characterized by recurring episodes of inflammation limited to mucosal and submucosal layers of the colon.
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Exacerbation, Protozoan Infections, Helminth Infection
- Trial name
- NCT03441893
- Testing
- parasitological diagnostics (coproscopy), Nitazoxanide 500Mg Oral Tablet, Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Chronic Obstructive Pulmonary Disease
ECCO2R as an Adjunct to NIV in AECOPD
Chronic obstructive pulmonary disease (COPD) is one of the UKs commonest chronic diseases and is responsible for a significant number of acute hospital admissions.
- Trial name
- NCT02086084
- Testing
- NIV, ECCO2R
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Chronic Obstructive Pulmonary Disease, COPD
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00076089
- Testing
- Roflumilast
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with…
- Trial name
- NCT07038876
- Testing
- ML-007C-MA BID, ML-007C-MA QD
- Where
- 24 sites in United States
- Volunteers
- 307 people
- Sponsor
- MapLight Therapeutics
Asthma, COPD
Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy
This study evaluates whether adding a spacer device to triple inhaled therapy (ICS/LABA/LAMA via pMDI) can reduce acute exacerbations in elderly patients (≥65 years) with stable chronic airway diseases (COPD or asthma) who are…
- Trial name
- NCT07030881
- Testing
- pMDI Triple Inhaler and Spacer, pMDI Triple Inhaler Only
- Where
- 9 sites in China
- Volunteers
- 380 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Bronchitis, Chronic
A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis
This study compared the clinical efficacy and safety of azithromycin with that of amoxicillin-clavulanic acid, in patients between the ages of 35 and 75 years, presenting with an exacerbation of chronic bronchitis.
- Trial name
- NCT00649831
- Testing
- Amoxicillin/clavulinic acid, Azithromycin
- Where
- 31 sites in France
- Volunteers
- 250 people
- Sponsor
- Pfizer
Asthma
The Predictors for Asthma Control by Stepwise Treatment During 6 Months in Korean Elderly
The Predictors for asthma control by stepwise treatment during 6 months in Korean elderly
- Trial name
- Prelude (NCT01370577)
- Where
- 5 sites in South Korea
- Volunteers
- 297 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.